(Q33909429)

29 July 2017

1 reference

title

Ursodeoxycholic acid for cystic fibrosis-related liver disease. (English)

1 reference

29 July 2017

0 references

K Cheng

1

1 reference

29 July 2017

D Ashby

series ordinal

2

1 reference

29 July 2017

R Smyth

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

published in

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

CD000222

1 reference

Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000222

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000222

The role of hepatobiliary scintigraphy in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000222

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000222

Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000222

Prevalence of liver disease in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000222

10.1002/14651858.CD000222

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference